GAM Systematic’s Haemonetics HAE Stock Holding History

GAM Systematic’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-15,850	Closed	-$626K	–	600
2017 Q2	$626K	Buy	15,850 +11,801	+291%	+$485K	0.09%	372
2017 Q1	$164K	Buy	+4,049	New	+$158K	0.03%	507

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

GAM Systematic's HAE Position: Q3 2017 in Review

GAM Systematic sold out of Haemonetics (HAE) in Q3 2017, closing a stake of 15,850 shares — an estimated $626K sold.

GAM Systematic first reported a position in HAE in Q1 2017 and held it in 2 quarters. The position peaked at $626K in Q2 2017. 207 funds tracked by Wall St. Rank hold HAE as of Q3 2017.

GAM Systematic reported no remaining Haemonetics position as of Q3 2017 after selling out during the quarter.
GAM Systematic sold 15,850 Haemonetics shares in Q3 2017, an estimated $626K.
GAM Systematic first reported a position in Haemonetics in Q1 2017 and held it in 2 quarters.
GAM Systematic's Haemonetics position peaked at $626K in Q2 2017.
207 funds tracked by Wall St. Rank held Haemonetics as of Q3 2017.

Based on GAM Systematic's 13F filing for Q3 2017, filed 14 Nov 2017.